Patients with diabetic macular edema or wet age-related macular degeneration who received a single injection of UBX1325 demonstrated “strong and sustained responses” at 12 weeks, according to a press release from Unity Biotechnology.
UBX1325, a small molecule inhibitor of Bcl-xL, targets a different biologic pathway from anti-VEGF therapies. The treatment has been well tolerated in the phase 1 clinical trial through 12 weeks with no treatment-related adverse events or dose-limiting toxicities.
Across all doses, eight of 12 patients gained best corrected visual acuity ETDRS letters